NEW YORK – The promise of blood-based multi-cancer early detection (MCED) tests was dealt an apparent blow in February when a large, randomized clinical trial in the UK failed to show that Grail's ...

NEW YORK – The US Food and Drug Administration has granted full approval to Gilead's CD19-directed CAR T-cell therapy Tecartus (brexucabtagene autoleucel) for patients with relapsed or refractory ...

The single-site, first-in-human Phase I trial will assess whether the therapy can kill cancer cells in patients who have become resistant to Venclexta.

Transgene has licensed the use of NEC's neoantigen prediction platform to support further development of the cancer vaccine TG4050.

The firm wants to obtain feedback from the agency on its proposed application for its autologous cell therapy for ischemic heart failure.

H-funded project will build a decision-making tool to help drugmakers and regulators predict treatments likely to work best ...

Data from the ATOMIC trial in the NEJM offers a practice-changing adjuvant immuno-chemo regimen for colon cancer, and have experts wondering about a chemo-free option.

Doctors and researchers discussed new broader testing guidelines and changing treatment practices for those with high Lp(a) ...

The European approval is based on results from the Phase III KEYNOTE-B96 trial, which also supported the regimen's approval in the US.

Voranigo will be immediately available to patients in England through the Cancer Drugs Fund while the MHRA conducts its regulatory review.